Clinical Trial Update: A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/phase 2 study evaluating the combination of binimetinib and encorafenib in advanced BRAF-mutant cancers has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf-mutant Cancers

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced BRAF Mutant Cancers | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-21